Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of Medicine

Posted:
22
December 2005

Richmond Pharmacology host ground breaking Early Phase Trials Integration seminar at the Royal Society of MedicineThe Early Phase Trials Integration seminar held recently at the Royal Society of Medicine was seen as a huge success by all who attended.The seminar generated valuable discussions between guest speakers and the Pharmaceutical industry, and explored innovative new ways to maximize the efficiency and speed of Early Phase research.The seminar focused on the developments around EU Legislations which have re-defined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases.World leading expert speakers from St George's University London, Mayday University Hospital & NHS trust and the ABPI outlined the new context within which clinical trials are conducted. Presentations on innovative new methodology were reviewed to identify how a CRO like Richmond Pharmacology can add value to pharmacology and patient studies.Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases.This new era of Early Phase research demands 3 foundations which were explored during the day:

  1. Commercial in- and out-patient facilities
  2. Acute NHS environment
  3. Therapeutic expertise

Delegate feedback has been positive. Everyone who attended benefited from the highly informative and educational day which was also accredited by the Faculty of Pharmaceutical Medicine (FPM).View presentations from the seminar

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more